Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients-Reference-Cited by-同舟云学术

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Published:2015-05-07 Issue:8 Volume:4 Page:e1026529
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Berinstein Neil L,Karkada Mohan,Oza Amit M,Odunsi Kunle,Villella Jeannine A,Nemunaitis John J,Morse Michael A,Pejovic Tanja,Bentley James,Buyse Marc,Nigam Rita,Weir Genevieve M,MacDonald Lisa D,Quinton Tara,Rajagopalan Rajkannan,Sharp Kendall,Penwell Andrea,Sammatur Leeladhar,Burzykowski Tomasz,Stanford Marianne M,Mansour Marc

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1026529

Reference38 articles.

1. Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)

2. Cancer immunotherapy – revisited

3. Checkpoint blocking antibodies in cancer immunotherapy

4. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

5. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

2. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives;Advances in Experimental Medicine and Biology;2024

3. Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap;Expert Opinion on Therapeutic Targets;2023-09-02

4. Antigenic targets in clear cell renal cell carcinoma;Kidney Cancer;2023-08-11

5. Evaluation of in vitro immunostimulatory and cytotoxic effects of recombinant survivin protein in combination with doxorubicin and breast cancer antigen-loaded polycaprolactone nanoparticles;Nano Futures;2023-07-06